{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T15:51:11Z","timestamp":1740153071856,"version":"3.37.3"},"reference-count":0,"publisher":"The Journal of Rheumatology","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"abstract":"Objective<\/jats:title>Prior incidence estimates of psoriatic arthritis (PsA) vary considerably. We aimed to assess the annual incidence of clinically diagnosed PsA among adults in Sweden in 2014-2016, overall and stratified by age\/sex\/education\/geography, and to investigate potential time trends in incidence in 2006-2018. Use of disease-modifying antirheumatic drugs (DMARDs) during the 2 years after diagnosis was also examined.<\/jats:p><\/jats:sec>Methods<\/jats:title>Patients (aged \u2265 18 years) with incident clinically diagnosed PsA in Sweden were identified from the National Patient Register (NPR) and\/or the Swedish Rheumatology Quality Register (SRQ). Population statistics, stratification variables, and DMARD information were retrieved from other nationwide registers. Incidence was estimated according to a base case (BC) definition (ie, \u2265 1 main International Classification of Diseases, 10th revision, diagnosis of PsA [L40.5\/M07.0-M07.3] from rheumatology\/internal medicine in NPR, or a PsA diagnosis in SRQ during the relevant year, and no prior such diagnoses) and 4 different sensitivity analysis case definitions.<\/jats:p><\/jats:sec>Results<\/jats:title>The mean annual incidence of clinically diagnosed PsA among adults in Sweden in 2014-2016 was estimated at 21.77 per 100,000 person-years (PYs) at risk, according to the BC definition; 17.41 per 100,000 PYs at risk after accounting for diagnostic misclassification; and 15.78 to 28.83 per 100,000 PYs at risk across all sensitivity analyses. Incidence was slightly higher in female individuals, was lower in those with higher education (aged > 12 years), and peaked during the ages of 50 to 59 years. No apparent increasing or decreasing time trend was observed in 2006-2018. Within 2 years of diagnosis, 71.03% of patients had received DMARD therapy (22.37% biologic or targeted synthetic DMARDs).<\/jats:p><\/jats:sec>Conclusion<\/jats:title>From 2014 to 2016, the annual incidence of clinically diagnosed PsA in the adult Swedish population was approximately 20 per 100,000 PYs at risk. Two years after diagnosis, almost three-quarters of patients had received DMARD therapy.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.2024-0376","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T05:37:38Z","timestamp":1726465058000},"page":"jrheum.2024-0376","source":"Crossref","is-referenced-by-count":0,"title":["Incidence of Clinically Diagnosed Psoriatic Arthritis in Sweden"],"prefix":"10.3899","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9261-7192","authenticated-orcid":false,"given":"Sofia","family":"Exarchou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3817-8288","authenticated-orcid":false,"given":"Daniela","family":"Di Giuseppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6858-6413","authenticated-orcid":false,"given":"Eva","family":"Klingberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9907-4901","authenticated-orcid":false,"given":"Valgerdur","family":"Sigurdardottir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2436-1519","authenticated-orcid":false,"given":"Sara","family":"Wedr\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2250-9348","authenticated-orcid":false,"given":"Ulf","family":"Lindstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3805-2290","authenticated-orcid":false,"given":"Carl","family":"Turesson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4402-148X","authenticated-orcid":false,"given":"Lennart T.H.","family":"Jacobsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0433-0616","authenticated-orcid":false,"given":"Johan","family":"Askling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4915-2924","authenticated-orcid":false,"given":"Johan K.","family":"Wallman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2024,9,15]]},"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2024-0376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T14:39:43Z","timestamp":1729003183000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2024-0376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,15]]},"references-count":0,"alternative-id":["10.3899\/jrheum.2024-0376"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2024-0376","relation":{},"ISSN":["0315-162X","1499-2752","0315-162X"],"issn-type":[{"type":"print","value":"0315-162X"},{"type":"electronic","value":"1499-2752"},{"type":"print","value":"0315-162X"}],"subject":[],"published":{"date-parts":[[2024,9,15]]}}}